Winterlight Technology Shows Positive Results In Study of Alzheimer’s Disease

Ontario Industry Updates
Written By Guest User

Winterlight’s (OBIO CAAP 2017 Company) cognitive assessment detected significant improvement for treatment relative to placebo in Cortexyme's Phase 1B trial for Alzheimer’s disease using COR388; a bacterial protease inhibitor.

Click here for more information

Guest User
Previous

OBIO Opens Canadian Health Investment Showcase in New York City, Connecting Canada’s High Potential Health Science Companies with Premier US Investors
Next

AGE-WELL Core Research Program 2020-2025 Request for Proposals Applications Now Open